Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.
You may also be interested in...
Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter
Chugai Pharmaceutical, the Japanese division of Roche, June 10 released new data on rheumatoid arthritis drug Actemra (tociluzumab), which showed that up to 56 percent of patients with active RA treated with Actemra for more than two years achieved disease remission. Presented at the European League Against Rheumatism annual congress, the remission data provides Roche and Chugai refreshed vigor on its push for still-pending U.S. approval for tociluzumab
Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter
Chugai Pharmaceutical, the Japanese division of Roche, June 10 released new data on rheumatoid arthritis drug Actemra (tociluzumab), which showed that up to 56 percent of patients with active RA treated with Actemra for more than two years achieved disease remission. Presented at the European League Against Rheumatism annual congress, the remission data provides Roche and Chugai refreshed vigor on its push for still-pending U.S. approval for tociluzumab
Roche Gears Up To Launch Actemra; Lines Up More Clinical Research In India
MUMBAI - Unperturbed by the spate of patent litigations, Swiss drug maker Roche is planning to bring into India Actemra (tocilizumab), its biological therapy indicated for the treatment of rheumatoid arthritis in adults and children